Regarding the therapeutic efficacy of DA and DAV treatments in patients with AML and different oncogenic backgrounds, despite the small number of patients in the subgroup, the DAV regimen resulted in a higher CR rate in patients bearing an NPM1 mutation, a KMT2A rearrangement, an FLT3‐ITD mutation, or RUNX1::RUNX1T1 compared to those under the DA regimen. The gene discussed is FLT3; the disease is acute myeloid leukemia.